ChemoCentryx to Hold Fourth Quarter and Full Year 2020 Financial Results Conference Call on Monday, March 1, 2021

Rhea-AI Summary

ChemoCentryx, Inc. (CCXI) will report its fourth quarter and full year 2020 financial results on March 1, 2021, after market close. A conference call to discuss these results will be held at 5:00 p.m. ET on the same day. Participants can join by dialing (877) 303-8028 for domestic calls or (760) 536-5167 for international calls, using conference ID 8283128. The call will also be available as a live and archived audio webcast on their website for 14 days. ChemoCentryx focuses on developing new medications for inflammatory, autoimmune diseases, and cancer.

Positive

• Lead drug candidate avacopan has completed a pivotal Phase III trial for ANCA-associated vasculitis.
• A New Drug Application for avacopan is currently under review by the FDA.
• Avacopan is also being developed for severe Hidradenitis Suppurativa and C3 glomerulopathy.

Negative

• None.

MOUNTAIN VIEW, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2020 financial results will be released after market close on Monday, March 1, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on March 1, 2021 to discuss these results and to answer questions.

To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 8283128. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

ChemoCentryx also has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:

Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
investor@chemocentryx.com 

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
Lee Roth, Burns McClellan
212.213.0006
lroth@burnsmc.com

FAQ

When will ChemoCentryx release its fourth quarter and full year 2020 financial results?

ChemoCentryx will release its financial results on March 1, 2021, after market close.

What is the conference call number for ChemoCentryx's financial results?

The conference call number is (877) 303-8028 for domestic and (760) 536-5167 for international calls.

What is the purpose of the conference call on March 1, 2021?

The conference call will discuss ChemoCentryx's fourth quarter and full year 2020 financial results.

What drug candidate is ChemoCentryx developing?

ChemoCentryx is developing avacopan as a treatment for various inflammatory and autoimmune diseases.